Ginger Root Extract for Sciatic Pain

This study is looking into whether ginger root extract can help people with chronic sciatic pain. Sciatic pain is a type of neuropathic pain (nerve pain) that affects many people. Researchers want to understand how ginger might work through the connection between the gut and the brain to reduce this pain. You would receive either ginger root extract or a placebo (an inactive substance like starch) daily for 8 weeks. To join, you need to be between 18 and 85 years old, have chronic sciatic pain for at least 3 months, and have a pain level of more than 3 out of 10. The study aims to see if ginger can reduce pain, measured by a pain inventory, and also to look at certain markers in your blood and stool related to gut health.

Study design
This is a randomized, double-blinded, and placebo-controlled study with 80 participants. Participants will be randomly assigned to receive either ginger or a placebo.
What's involved
You would take either ginger root extract or a placebo daily for 8 weeks. Measurements of blood, stool, and pain levels will be taken at the beginning and after 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be measured at the start of the study and again after 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06817018

Ginger Root Extract for Sciatic Pain Individuals

Recruiting
PHASE2Ages 18–85InterventionalTreatment
Leslie Shen
~80 participants
Updated 2025-12-30 on ClinicalTrials.gov
What's tested:PlaceboGinger

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
plasma lipopolysaccharide binding protein (LBP)
Measured over baseline and after 8 weeks
+3 more outcomes measured
Neuropathic Pain
Sciatic Pain
2 sites across 1 states
Texas2

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-85 years old men and women with BMI \< 25 or ≥ 30 kg/m2
low back or gluteal pain radiating into leg(s) past the knee (sciatica) with pain duration of at least 3 months (chronic sciatica)
pain scale \> 3 out of 10 (0=no pain,10=worst pain imaginable) during the past 24 hours
willingness to accept randomization.
woman of childbearing potential agrees to use an effective form of contraception during the study

Exclusion

known or suspected serious spinal pathology (e.g., cauda equina syndrome or spinal fracture)
scheduled, or being considered, for spinal surgery or interventional procedures for sciatica during study period
focal neurological deficits with progressive or disabling symptoms
low back pain without sciatica
unstable GI disorder
history of chronic or systemic autoimmune diseases with GI involvement
recent (\<1 month) appearance of diarrhea or hematochezia before study begins
recent (\<1 month) exposure to antibiotics before study start
pregnant or breast-feeding women
women of child-bearing potential will have a urine pregnancy test done prior to the baseline MRI and administration of any study drug. The clinical research coordinator will run the pregnancy test and inform the patient of the results. If the test is positive, they will be withdrawn from study participation.
cognitive impairment, history of psychiatric conditions indicating mental health instability or incapacity
likeliness of moving during the trial, lack of transportation, or unavailability at sample collection times.
presence of a bleeding diathesis
taking anticoagulant medications (e.g Heparin, Warfarin)
taking dual antiplatelet medications (e.g. aspirin + Plavix)
participants with clinically significant laboratory abnormalities of liver function (AST and ALT) and kidney function (BUN and serum creatinine) abnormalities. Definition of clinically significant for liver function is AST/ALT ≥ 3.0x ULN and for kidney function is serum creatinine \> 2.0 mg/dl and BUN \> 1.5x ULN.
  • plasma lipopolysaccharide binding protein (LBP)baseline and after 8 weeks

    Intestinal permeability biomarker

  • fecal zonulinbaseline and after 8 weeks

    intestinal permeability marker

  • brief pain inventory (BPI)baseline and after 8 weeks

    pain assessment

  • SF-MPQbaseline and after 8 weeks

    pain assessment